Highest-materiality recent filing
Bicycle Therapeutics shareholders approve all proposals at 2026 AGM
98.64% of shares represented; all 9 proposals passed with large majorities.
Bicycle Therapeutics reports positive Duravelo-2 mUC data with lower toxicity vs SOC
Zelenectide + pembrolizumab: 58% confirmed ORR (15/26) at optimal dose in first-line mUC; 62% with later response.
Bicycle Therapeutics Q1 2026 net loss $60.8M, restructures, cuts 30% staff
Net loss $60.8M ($0.87/sh) flat YoY; collaboration revenue dropped to $0.9M from $10.0M.
Bicycle Therapeutics: nuzefatide 40% ORR in EphA2+ mUC; Phase 2 PDAC trial dosed
Nuzefatide + nivolumab in 14 mUC patients: 40% ORR in EphA2+ tumors; 100% ORR (3/3) in MMAE-naïve EphA2+ tumors.
Deprioritizes zelenectide in mUC; converts Duravelo-2 to randomized Phase 2 after regulatory feedback says trial design no longer acceptable for approval.
Bicycle Therapeutics appoints Travis Thompson as CFO, succeeding Alethia Young
Travis Thompson appointed CFO effective Jan 29, 2026; previously SVP & Chief Accounting Officer since June 2023.
Dose selection from Phase 2/3 Duravelo-2 trial and approval update for zelenectide pevedotin in mUC expected in Q1 2026
Bicycle Therapeutics Q3 net loss $59.1M; lead drug regulatory update delayed to Q1 2026
Net loss of $59.1M ($0.85 per share) vs $50.8M ($0.74) in Q3 2024; R&D expenses up 21% to $58.4M.
Bicycle Therapeutics appoints Roger Dansey and Hervé Hoppenot to Board of Directors
Roger Dansey, M.D. (ex-Pfizer/Seagen) and Hervé Hoppenot (ex-Incyte/Novartis) joined the board effective Sep 8, 2025.
Bicycle Therapeutics Q2 net loss widens to $1.14/share; cuts workforce 30% to extend runway
Net loss $79.0M ($1.14/share) vs $39.8M ($0.77) a year ago; R&D spend rose 77% to $71.0M.
Bicycle Therapeutics AGM results: all proposals pass, equity plan amendment sees 22.4% opposition
Re-elected director Alessandro Riva: 40.0M for, 9.1M against (18.5% opposed).
Bicycle Therapeutics Q1 net loss $60.8M; cash $793M; Duravelo-3 trial recruiting
Net loss of $60.8M ($0.88 per share) vs $26.6M ($0.62) in Q1 2024; R&D expense $59.1M (+69% YoY).
Data from 12 patients validate MT1-MMP as cancer target; BRC tracer showed uptake in primary tumors and metastases.
Pierre Legault and Richard Kender to retire from board after AGM June 17, 2025; Felix Baker to become chairman.
Bicycle Therapeutics sets June 17, 2025 for annual meeting; announces proposal deadlines
2025 Annual General Meeting set for June 17, 2025; location and time in proxy statement.
Cash and cash equivalents $879.5M as of Dec 31, 2024, providing runway into 2H 2027.
Updated Phase 1 Duravelo-1 data: 65% ORR (13/20 evaluable) in 1L cisplatin-ineligible mUC; 50% confirmed ORR.
Bicycle Therapeutics Reports Positive Zelenectide Pevedotin Data in Multiple Cancers
Zelenectide pevedotin plus pembrolizumab showed 60% ORR in 22 first-line cisplatin-ineligible mUC patients.
Net loss $50.8M ($0.74/shr) in Q3 2024 vs $49.9M ($1.26/shr) in Q3 2023; R&D spend $48.3M, up from $39.9M.
First human imaging data validate MT1-MMP BRC radiopharmaceutical potential; strategy outlined
First human PET/CT data for gallium-68-labelled MT1-MMP BRC show tracer uptake in lung cancer primary and metastases consistent with FDG imaging.
Bicycle Therapeutics reports positive ESMO 2024 data: 45% ORR for zelenectide pevedotin in mUC
Zelenectide pevedotin monotherapy in mUC: 45% ORR (38 evaluable patients), 11.1 months median duration of response.
Bicycle Therapeutics Q2 net loss $39.8M; cash $961.4M after $555M PIPE
Net loss of $39.8M ($0.77 loss per share) vs $42.6M ($1.41 loss per share) in Q2 2023; R&D expense $40.1M.
Bicycle Therapeutics terminates $30M Hercules loan, repays $31.9M total
Repaid $30.0M principal plus $1.5M end-of-term charge and $0.3M prepayment fee, total $31.9M.
Bicycle Therapeutics registers 37.7M shares for resale by selling securityholders
Filed prospectus supplement to resell up to 37,656,764 ordinary shares (each represented by one ADS).
Sold 25,933,706 ADSs (and non-voting ordinary shares in lieu) at $21.42/share for gross proceeds of ~$555M.
Bicycle Therapeutics shareholders approve all 11 proposals at 2024 AGM
Directors Kevin Lee (36.4M for) and Jose-Carlos Gutierrez-Ramos (35.0M for) re-elected.
Bicycle Therapeutics Q1 net loss narrows to $26.6M; cash $457M; Phase 2/3 trial initiated
Cash and equivalents $457.0M as of Mar 31, 2024, down from $526.4M at Dec 31, 2023.
Bicycle Therapeutics appoints Felix Baker to board; Jordan resigns, becomes consultant
Veronica Jordan resigned as director April 17; will serve as consultant at GBP 12,000/yr for 2-year term, equity continues vesting.
Bicycle Therapeutics Q4 net loss $49.1M; cash $526.4M; BT8009 Phase 2/3 trial recruiting
Net loss $49.1M ($1.16/share) in Q4 2023 vs $30.0M prior year; full year loss $180.7M ($5.08).
BT8009 showed 38% ORR in 26 EV-naïve mUC patients; median duration of response 11.1 months; zero severe peripheral neuropathy.
Bicycle Therapeutics Q3 net loss $49.9M; FDA aligns on BT8009 Phase 2/3 trial for bladder cancer
Net loss $49.9M ($1.26/share) vs $28.3M ($0.96/share) in Q3 2022; R&D expenses rose to $39.9M.
FDA alignment reached on Duravelo-2 trial design; trial to begin Q1 2024.
Bicycle Therapeutics Q2 net loss widens to $1.41/sh; cash >$600M after $230M raise
Net loss $42.6M ($1.41 loss per share) vs $26.8M ($0.90) a year ago; R&D expense doubled to $39.7M.
Bicycle Therapeutics raises ~$187M net in public offering of 9.4M ADSs at $21.25/sh
Public offering of 9,411,766 ADSs (or non-voting ordinary shares) at $21.25 per share; net proceeds ~$187.3M.
Bicycle Therapeutics appoints Alethia Young as CFO, replaces Lee Kalowski
Alethia Young appointed CFO effective ~July 17, 2023; Lee Kalowski resigned effective June 22, 2023.
Bicycle Therapeutics shareholders pass all 10 proposals at 2023 AGM
Approximately 91.77% of outstanding ordinary shares voted; proposals passed with overwhelming support.
Bicycle Therapeutics registers up to $150M additional ADS sale under ATM facility
Filed prospectus supplement on May 26, 2023, to sell up to $150M in ADSs via existing Sales Agreement with Cantor Fitzgerald and Oppenheimer.
Bayer and Bicycle Therapeutics enter $1.7B collaboration for radiopharmaceuticals; $45M upfront
Bicycle receives $45M upfront; total potential milestones up to $1.7B across up to three oncology targets.
Bicycle Therapeutics Q1 net loss $39.1M; cash $293.8M; Novartis deal advances BRC pipeline
Net loss of $39.1M ($1.30 per share) vs $27.6M ($0.93 per share) in Q1 2022.
Bicycle Therapeutics appoints Dr. Arroyo as CDO, promotes Perry to SVP Commercial; CMO leaves
Santiago Arroyo appointed Chief Development Officer effective March 31, 2023; formerly CMO at Momenta and Fulcrum.
Bicycle Therapeutics receives $50M upfront from Novartis to discover Bicycle radio-conjugates for oncology targets.
Bicycle Therapeutics reports FY2022 net loss of $112.7M; cash $339.2M, runway into 2025
Net loss of $30.0M in Q4 2022 ($1.01/share) and $112.7M for FY2022 ($3.80/share), vs $18.0M and $66.8M in prior year.
Bicycle Therapeutics announces Phase I BT8009 results: 50% ORR in urothelial cancer, well tolerated
50% overall response rate (ORR) and 75% clinical benefit rate in urothelial cancer at 5 mg/m2; one complete response.
Bicycle Therapeutics increases change-in-control severance for CEO, CFO, and CTO
CEO Kevin Lee receives 24 months' base salary and benefits on change-of-control termination; subject to shareholder approval.
BT8009 Phase II expansion first patient dosed; Phase I dose escalation complete
Phase I dose escalation complete; RP2Ds: 5 mg/m2 weekly and 7.5 mg/m2 (2 on, 1 off) selected.
Bicycle Therapeutics reports Q3 net loss $28.3M; cash $361.5M; clinical pipeline progressing
Net loss of $28.3M ($0.96 per share) vs $14.7M ($0.59) in Q3 2021.
Among 9 EphA2-positive ovarian patients, ORR 22% (1 CR, 1 PR), DCR 67%; median 4 prior therapies.
Bicycle Therapeutics reports Q2 net loss $26.8M, cash $372.8M; Genentech expands collaboration
Net loss $26.8M ($0.90/share) vs $17.9M ($0.74) in Q2 2021, driven by higher R&D and G&A costs.
Term Loan Maturity Date extended to July 1, 2025; Amortization Date moved to April 1, 2025.
Genentech exercised second option to add a new program to the existing 2020 collaboration, triggering a $10M payment to Bicycle.
On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.
Santiago Arroyo, M.D., Ph.D., notified the Board of his resignation as the Company's Chief Development Officer, effective March 24, 2025.
On March 27, 2025, the Company also announced that Pierre Legault, MBA, CPA, and Richard Kender, MBA, would not be standing for re-election at the 2025 Annual Meeting, and that each of Mr. Legault and Mr. Kender would retire from the Board effective immediately following the 2025 Annual Meeting.
appointed Alessandro Riva, M.D., to the Board and the Scientific Committee of the Board, effective as of the close of business on March 25, 2025, New York City time.
On April 16, 2024, the Board , upon the recommendation of the Nominating and Corporate Governance Committee of the Company (the “ NCGC ”), appointed Felix J. Baker, Ph.D. to the Board, effective as of April 18, 2024, New York City time.
On April 16, 2024, Veronica Jordan, Ph.D. notified the Board of Directors of the Company (the “ Board ”) of her decision to resign as a Class I director of the Company and as the Chair of the Compensation Committee of the Board and as a member of the Audit Committee of the Board, effective as of the close of business on April 17, 2024, New York City time.
On February 20, 2024, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Nominating & Corporate Governance Committee of the Board, appointed Stephen Sands to the Board, effective as of the close of business on February 20, 2024, New York City time.
the Board appointed Travis Thompson as the Company’s Chief Accounting Officer and principal accounting officer, effective as of the Transition Date
the Board of Directors (the “ Board ”) of Bicycle Therapeutics plc (the “ Company ”) appointed Alethia Young as Chief Financial Officer and principal financial officer, effective on or about July 17, 2023
On January 5, 2022, Bicycle Therapeutics plc (the “Company”) announced the appointment of Alistair Milnes, age 48, as the Company’s Chief Operating Officer, effective as of January 3, 2022
following the transition of Michael Skynner, Ph.D. to the newly-created role of Chief Technology Officer of the Company as of the Effective Date.
Max materiality 0.90 · Median 0.68 · Most common event other_material